Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
COP$139.40+2.46(+1.80%)ConocoPhillips Q3 profit beats on higher prices, hikes dividend7:26:13 AM ETMETA$636.83+6.83(+1.08%)UPDATE 2-Meta sells first bonds in euros, raises €9 billion7:25:25 AM ETDTE$138.25+3.99(+2.97%)UPDATE 1-DTE Energy to sell its non-utility business for about $3 billion7:23:30 AM ETAAPL$352.33+2.82(+0.81%)Jim Cramer's Surprise Midterm Winner: Apple, Because Fewer Data Centers Could Mean Cheaper Memory7:19:09 AM ETMU$762.31-33.15(-4.17%)Could Buying Micron Stock Today Help Set You Up for Life?7:17:00 AM ETMSFT$555.46-0.34(-0.06%)Microsoft Is Executing an Irreproducible Balance-Sheet-Backed Infrastructure Pre-Sale at Scale7:15:58 AM ETAAPL$352.33+2.82(+0.81%)Apple Vs. Tesla: Low CapEx Only Matters if Non-Cyclical Cash Flows Come With It7:15:57 AM ETIREN$20.93-0.77(-3.55%)IREN is Only Fit for a Specific Investor Currently7:15:22 AM ETCOP$139.40+2.46(+1.80%)BRIEF-Conocophillips Q3 Adjusted EPS USD 3.27 Vs. IBES Estimate USD 2.977:13:20 AM ETMU$762.31-33.15(-4.17%)Micron Just Closed Below $800 for the First Time Since July7:12:48 AM ETCOP$139.40+2.46(+1.80%)ConocoPhillips beats profit estimates, boosts quarterly dividend7:11:13 AM ETCRWD$233.65-7.35(-3.05%)Too Late to Buy CrowdStrike Stock? Here's the 1 Thing to Watch.7:10:00 AM ETGOOG$290.80+3.50(+1.22%)These 6 Stocks Make Up a Big Share of the S&P 5007:09:00 AM ETCOP$139.40+2.46(+1.80%)UPDATE 1-ConocoPhillips beats profit estimates, boosts quarterly dividend7:07:07 AM ETLLY$1,430.00+11.86(+0.84%)Iconic California Brand, French Florist, Celebrates Grand Opening of First Indiana Location7:07:00 AM ETCVS$81.00+1.01(+1.26%)ProjectLeo, the First Private AI Health Platform to Declare Independence From Big Tech7:04:00 AM ETCOP$139.40+2.46(+1.80%)ConocoPhillips beats quarterly profit estimates7:01:40 AM ETCOP$139.40+2.46(+1.80%)ConocoPhillips announces third-quarter 2026 results and increases quarterly ordinary dividend by 11%7:00:05 AM ETPG$168.66+1.34(+0.80%)P&G to Webcast Presentation From P&G Investor Day 2026, November 197:00:03 AM ETV$440.17+3.58(+0.82%)Visa Forecasts U.S. Holiday Spending to Rise 4.5% as Consumers Keep the Holidays a Priority7:00:00 AM ETHD$360.19+4.75(+1.34%)Transom Appoints David Shields as Executive Vice President, Operations and Finance7:00:00 AM ETGS$937.89+9.61(+1.04%)RPT-BREAKINGVIEWS-Hong Kong summit exposes Wall Street AI confusion7:00:00 AM ETDTE$138.25+3.99(+2.97%)DTE Energy to sell DTE Vantage business for about $3 billion6:59:28 AM ETACN$268.00+3.73(+1.41%)Mondelēz International and Accenture Transform Order-to-Cash With AI6:59:02 AM ET

DTIL · NASDAQ

Precision BioSciences, Inc.

$8.21 +0.09 (+1.11%)

Company overview

Precision BioSciences, Inc. is a clinical-stage gene editing company that develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company offers ARCUS, a genome editing platform designed to cure genetic disorders. It also provides ex vivo allogeneic CAR T immunotherapy, a form of immunotherapy in which T cells, a specific type of immune cell, are genetically engineered to recognize and kill cancer cells. The company's pipeline includes PBCAR0191, which is in a Phase 1/2a clinical trial in adult patients with relapsed or refractory non-Hodgkin lymphoma or relapsed or refractory B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy target…

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$227M
Employees
108
Headquarters
Durham, NC
Website
precisionbiosciences.com
CEO
Juli Blanche
Listed
March 28, 2019
P/E
-1.88
Dividend yield
0.00%

Company financials

Revenue
$45.1M
Gross profit
$43.7M
Operating income
-$39.1M
EBITDA
-$31.4M
Net income
-$44.5M
EPS
-$4.35
Total assets
$144M
Total debt
$28.5M
Gross margin
96.95%
Net margin
-98.70%
Earnings yield
-53.11%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

5.566.627.678.729.78
DTIL 1D NASDAQ O7.21H8.13L7.14C8.12+1.15 (+16.50%)Vol341.87K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting® 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure Business Wire
DTILPrecision BioSciences, Inc. Stock news Precision BioSciences Q3 net loss narrows on non-cash warrant gains Reuters
DTILPrecision BioSciences, Inc. Stock news BRIEF-Precision BioSciences, Inc. Q3 Income From Operations USD -20.428 Million Reuters
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026 Business Wire
DTILPrecision BioSciences, Inc. Stock news Precision BioSciences (NASDAQ:DTIL) Stock Price Breaks Below 200 Day Moving Average – Time to Sell? Defense World
DTILPrecision BioSciences, Inc. Press release Arcus Biosciences Announces New Employment Inducement Grants Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 Business Wire
DTILPrecision BioSciences, Inc. Press release iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026 Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study Business Wire
DTILPrecision BioSciences, Inc. Press release iECURE to Present Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM Annual Symposium Business Wire
DTILPrecision BioSciences, Inc. Stock news Precision BioSciences: Promising HBV Editing Evidence Seeking Alpha
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones Business Wire
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
DTILPrecision BioSciences, Inc. Stock news Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength? Zacks Investment Research
DTILPrecision BioSciences, Inc. Press release Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors Business Wire
See more
FAQ

Questions about Precision BioSciences, Inc.

What does Precision BioSciences, Inc. do?
Precision BioSciences, Inc. is a clinical-stage gene editing company that develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company offers ARCUS, a genome editing platform designed to cure genetic disorders. It also provides ex vivo allogeneic CAR T immunotherapy, a form of immunotherapy in which T cells, a specific type of immune cell, are genetically engineered to recognize and kill cancer cells. The company's pipeline includes PBCAR0191, which is in a Phase 1/2a clinical trial in adult patients with relapsed or refractory non-Hodgkin lymphoma or relapsed or refractory B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy target…
What is DTIL's market cap?
Precision BioSciences, Inc. (DTIL) is a listed stock with a live quote. The latest market cap on this page is $227M.
Where is Precision BioSciences, Inc. headquartered?
Precision BioSciences, Inc. is headquartered in Durham, NC.
How do I get DTIL news from the API?
Call GET /v1/news?tickers=DTIL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does DTIL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for DTIL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the DTIL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs